148 related articles for article (PubMed ID: 9816335)
41. p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization.
Akashi M; Osawa Y; Koeffler HP; Hachiya M
Biochem J; 1999 Feb; 337 ( Pt 3)(Pt 3):607-16. PubMed ID: 9895308
[TBL] [Abstract][Full Text] [Related]
42. p53-dependent p21 induction following gamma-irradiation without concomitant p53 induction in a human peripheral neuroepithelioma cell line.
Isaacs JS; Chiao C; Merrick BA; Selkirk JK; Barrett JC; Weissman BE
Cancer Res; 1997 Jul; 57(14):2986-92. PubMed ID: 9230213
[TBL] [Abstract][Full Text] [Related]
43. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma.
Moriyama Y; Nishiguchi S; Tamori A; Koh N; Yano Y; Kubo S; Hirohashi K; Otani S
Clin Cancer Res; 2001 May; 7(5):1293-8. PubMed ID: 11350897
[TBL] [Abstract][Full Text] [Related]
44. Comparative evaluation of the expression of cell cycle regulating proteins: cyclin D1, P53 and P21 (WAF1) in colorectal cancer.
Pasz-Walczak G; Kordek R
Pol J Pathol; 2000; 51(2):63-9. PubMed ID: 10974928
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary.
Werness BA; Freedman AN; Piver MS; Romero-Gutierrez M; Petrow E
Gynecol Oncol; 1999 Dec; 75(3):413-8. PubMed ID: 10600299
[TBL] [Abstract][Full Text] [Related]
46. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Szepeshazi K; Schally AV; Halmos G; Armatis P; Hebert F; Sun B; Feil A; Kiaris H; Nagy A
Cancer Res; 2002 Feb; 62(3):781-8. PubMed ID: 11830533
[TBL] [Abstract][Full Text] [Related]
47. Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway.
Takagaki N; Sowa Y; Oki T; Nakanishi R; Yogosawa S; Sakai T
Int J Oncol; 2005 Jan; 26(1):185-9. PubMed ID: 15586239
[TBL] [Abstract][Full Text] [Related]
48. Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis.
Kobayashi T; Consoli U; Andreeff M; Shiku H; Deisseroth AB; Zhang W
Oncogene; 1995 Dec; 11(11):2311-6. PubMed ID: 8570182
[TBL] [Abstract][Full Text] [Related]
49. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.
Havrilesky LJ; Hurteau JA; Whitaker RS; Elbendary A; Wu S; Rodriguez GC; Bast RC; Berchuck A
Cancer Res; 1995 Feb; 55(4):944-8. PubMed ID: 7531618
[TBL] [Abstract][Full Text] [Related]
50. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.
Skilling JS; Squatrito RC; Connor JP; Niemann T; Buller RE
Gynecol Oncol; 1996 Jan; 60(1):72-80. PubMed ID: 8557231
[TBL] [Abstract][Full Text] [Related]
51. Monitoring adenoviral p53 transduction efficiency by yeast functional assay.
Tada M; Sakuma S; Iggo RD; Saya H; Sawamura Y; Fujiwara T; Roth JA
Gene Ther; 1998 Mar; 5(3):339-44. PubMed ID: 9614553
[TBL] [Abstract][Full Text] [Related]
52. p53-dependent induction of WAF1 by cold shock in human glioblastoma cells.
Ohnishi T; Wang X; Ohnishi K; Takahashi A
Oncogene; 1998 Mar; 16(11):1507-11. PubMed ID: 9525749
[TBL] [Abstract][Full Text] [Related]
53. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
[TBL] [Abstract][Full Text] [Related]
54. Altered topographic expression of p21WAF1/CIP1/SDI1, bcl2 and p53 during gastric carcinogenesis.
Cho JH; Kim WH
Pathol Res Pract; 1998; 194(5):309-17. PubMed ID: 9651943
[TBL] [Abstract][Full Text] [Related]
55. Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells.
Wyllie FS; Haughton MF; Blaydes JP; Schlumberger M; Wynford-Thomas D
Oncogene; 1995 Jan; 10(1):49-59. PubMed ID: 7529918
[TBL] [Abstract][Full Text] [Related]
56. Overexpression and mutation of p53 in epithelial ovarian cancer.
Marks JR; Davidoff AM; Kerns BJ; Humphrey PA; Pence JC; Dodge RK; Clarke-Pearson DL; Iglehart JD; Bast RC; Berchuck A
Cancer Res; 1991 Jun; 51(11):2979-84. PubMed ID: 2032235
[TBL] [Abstract][Full Text] [Related]
57. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate.
Chen YM; Chen PL; Arnaiz N; Goodrich D; Lee WH
Oncogene; 1991 Oct; 6(10):1799-805. PubMed ID: 1923505
[TBL] [Abstract][Full Text] [Related]
58. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.
Isaacs WB; Carter BS; Ewing CM
Cancer Res; 1991 Sep; 51(17):4716-20. PubMed ID: 1873816
[TBL] [Abstract][Full Text] [Related]
59. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma.
Bhatia K; Fan S; Spangler G; Weintraub M; O'Connor PM; Judde JG; Magrath I
Cancer Res; 1995 Apr; 55(7):1431-5. PubMed ID: 7882347
[TBL] [Abstract][Full Text] [Related]
60. Growth suppression of normal mammary epithelial cells by wild-type p53.
Merlo GR; Venesio T; Taverna D; Marte BM; Callahan R; Hynes NE
Oncogene; 1994 Feb; 9(2):443-53. PubMed ID: 8290256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
